Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
BEVERLY, Mass. and TORONTO, Ontario, Aug. 16, 2017 -- Hamilton Thorne Ltd. (TSX-V:HTL), a leading world-wide provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets, today announced that it will release its financial results for the three and six months ended June 30, 2017 before the market opens on Tuesday, August 22, 2017. The press release, with accompanying financial information, will be posted on the Company’s website at www.hamiltonthorne.com and on www.sedar.com.
The Company will follow with a conference call Tuesday, August 22, 2017, at 11:00 a.m. EDT to review highlights of its quarterly results. All interested parties are welcome to join the conference call by dialing toll free 1-855-223-7309 in North America, or 647-788-4929 from other locations, and requesting Conference ID 72072012. A recording of the call will be available on Hamilton Thorne’s website no later than five business days after the call.
About Hamilton Thorne Ltd. (www.hamiltonthorne.com)
Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.
Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.
For more information, please contact: David Wolf, President & CEO Hamilton Thorne Ltd. 978-921-2050 [email protected] Michael Bruns, CFO Hamilton Thorne Ltd 978-921-2050 [email protected]
